BMO Capital Starts Inflarx NV (IFRX) at Outperform

BMO Capital initiates coverage on Inflarx NV (NASDAQ: IFRX) with a Outperform rating and a price target of $45.00.

Analyst Matthew Luchini commented, "We believe IFX-1 could be a best-in-class treatment for hidradenitis suppurativa (HS), a debilitating chronic skin disease. We believe initial data suggests IFX-1 could have a better clinical profile than market leader Humira. We believe the strength of IFX-1’s Phase IIa HS data de-risks the ongoing Phase IIb trial (data 1H19), while IFX-1’s targeting of C5a could be an advantage over emerging competitor avacopan, which targets only C5aR. We leave IFX-1’s second indication, ANCA-associated vasculitis (AAV), another rare and potentially fatal autoimmune disease, and the preclinical pipeline as upside."

For an analyst ratings summary and ratings history on Inflarx NV click here. For more ratings news on Inflarx NV click here.

Shares of Inflarx NV closed at $30.31 yesterday.

You May Also Be Interested In

• BofA Securities Starts GE Vernova (GEV) at Neutral, 'Multiyear turnaround amid positive demand backdrop'
• GATX Corp. (GATX) PT Raised to $137 at TD Cowen
• Goldman Sachs Starts Victoria's Secret (VSCO) at Sell